| Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6564 | 2015 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ... Journal of Clinical Oncology 36 (17), 1714-1768, 2018 | 3608 | 2018 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2552 | 2017 |
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ... Journal of Clinical Oncology 27 (8), 1227-1234, 2009 | 1954 | 2009 |
| Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial C Zimmermann, N Swami, M Krzyzanowska, B Hannon, N Leighl, A Oza, ... The Lancet 383 (9930), 1721-1730, 2014 | 1859 | 2014 |
| Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ... Journal of Clinical Oncology 37 (28), 2518-2527, 2019 | 1077 | 2019 |
| Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update TJ Smith, K Bohlke, GH Lyman, KR Carson, J Crawford, SJ Cross, ... Journal of Clinical Oncology 33 (28), 3199-3212, 2015 | 924 | 2015 |
| Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III … M Reck, J Von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ... Annals of oncology 21 (9), 1804-1809, 2010 | 784 | 2010 |
| Sensitive tumour detection and classification using plasma cell-free DNA methylomes SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ... Nature 563 (7732), 579-583, 2018 | 743 | 2018 |
| Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis RG Hagerty, PN Butow, PM Ellis, EA Lobb, SC Pendlebury, N Leighl, ... Journal of clinical oncology 23 (6), 1278-1288, 2005 | 731 | 2005 |
| Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ... Journal of Clinical Oncology 35 (30), 3484-3515, 2017 | 690 | 2017 |
| CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced … T Reungwetwattana, K Nakagawa, BC Cho, M Cobo, EK Cho, A Bertolini, ... Journal of Clinical Oncology 36 (33), 3290-3297, 2018 | 687 | 2018 |
| Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial DW Kim, M Tiseo, MJ Ahn, KL Reckamp, KH Hansen, SW Kim, RM Huber, ... Journal of Clinical Oncology 35 (22), 2490-2498, 2017 | 637 | 2017 |
| Cancer patient preferences for communication of prognosis in the metastatic setting RG Hagerty, PN Butow, PA Ellis, EA Lobb, S Pendlebury, N Leighl, ... Journal of clinical oncology 22 (9), 1721-1730, 2004 | 587 | 2004 |
| Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes JD McKay, RJ Hung, Y Han, X Zong, R Carreras-Torres, DC Christiani, ... Nature genetics 49 (7), 1126-1132, 2017 | 573 | 2017 |
| Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer NB Leighl, RD Page, VM Raymond, DB Daniel, SG Divers, KL Reckamp, ... Clinical cancer research 25 (15), 4691-4700, 2019 | 498 | 2019 |
| Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology … GP Kalemkerian, N Narula, EB Kennedy, WA Biermann, J Donington, ... Journal of Clinical Oncology 36 (9), 911-919, 2018 | 497 | 2018 |
| Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature G D'Addario, M Pintilie, NB Leighl, R Feld, T Cerny, FA Shepherd Journal of clinical oncology 23 (13), 2926-2936, 2005 | 494 | 2005 |
| Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ... Journal of Clinical Oncology 39 (30), 3391-3402, 2021 | 491 | 2021 |
| Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ... Journal of Clinical oncology 33 (8), 910-915, 2015 | 468 | 2015 |
Ming TsaoUniversity of Toronto, University Health Network, Princess Margaret Cancer Centre在 uhn.ca 的电子邮件经过验证
